All In MedTech

Device Trial Radar · NCT06135727

Screening Protocol

Data Collection for Development of Topcon Health Score

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

26

Actual

Start

Nov 7, 2023

Primary completion

Aug 2, 2024

Study completion Aug 2, 2024

Sponsor

Lead sponsor
Topcon CorporationNot on our public-company list
Sponsor type
Industry
First posted
Nov 18, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to collect data for the development and validation a screening process using aggregate data. In this study, data collection will encompass both retrospective and prospective approaches across multiple sites in the United States.

Conditions

  • Glaucoma

Interventions

  • Maestro2 OCTDevice

    3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RNFL and GCL thicknessTime frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Topcon

    La Jolla, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.